University of Dundee Interferon lambda 4 impacts the genetic diversity of hepatitis C virus
暂无分享,去创建一个
C. Spencer | P. Klenerman | P. Simmonds | Arvind H. Patel | R. Bowden | Camilla L. C. Ip | E. Barnes | V. Pedergnana | J. McLauchlan | W. Irving | A. Trebes | P. Piazza | M. Ansari | E. Aranday-Cortes | S. H. Lau | Connor G. G. Bamford | D. Bonsall | V. Sreenu | V. Cowton | G. Foster | C. Holmes | E. Hudson | E. Thomson | K. Agarwal | Vanessa M. Cowton | A. Filipe | C. Bamford | A. Patel
[1] A. Tarr,et al. Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection , 2019, Hepatology.
[2] David Smith,et al. Interpreting Viral Deep Sequencing Data with GLUE , 2019, Viruses.
[3] S. Tishkoff,et al. A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages , 2018, bioRxiv.
[4] C. Spencer,et al. Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus , 2017 .
[5] G. Gerold,et al. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy , 2017, Journal of immunology research.
[6] B. Walker,et al. HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] B. Pierce,et al. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design , 2016, Proceedings of the National Academy of Sciences.
[8] A. Walker,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[9] X. Didelot,et al. Bayesian Inference of the Evolution of a Phenotype Distribution on a Phylogenetic Tree , 2016, Genetics.
[10] J. Miquel,et al. Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[12] P. Klenerman,et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design , 2015, Gut.
[13] H. Drummer,et al. Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection , 2015, PloS one.
[14] D. Gatherer,et al. Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[15] H. Nomura,et al. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection , 2015, Journal of Gastroenterology.
[16] Z. Kutalik,et al. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.
[17] D. Tyrrell,et al. Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. , 2014, The Journal of infectious diseases.
[18] A. Tarr,et al. The past, present and future of neutralizing antibodies for hepatitis C virus , 2014, Antiviral research.
[19] Gad Abraham,et al. Fast Principal Component Analysis of Large-Scale Genome-Wide Data , 2014, bioRxiv.
[20] Alexandros Stamatakis,et al. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..
[21] Robyn L. Stanfield,et al. Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.
[22] T. Liang,et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis , 2013, Hepatology.
[23] P. Simmonds,et al. Modelling mutational and selection pressures on dinucleotides in eukaryotic phyla –selection against CpG and UpA in cytoplasmically expressed RNA and in RNA viruses , 2013, BMC Genomics.
[24] Matti Pirinen,et al. Imputation-Based Meta-Analysis of Severe Malaria in Three African Populations , 2013, PLoS genetics.
[25] Barbara Rehermann,et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.
[26] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[27] O. Delaneau,et al. Supplementary Information for ‘ Improved whole chromosome phasing for disease and population genetic studies ’ , 2012 .
[28] Z. Kutalik,et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. , 2012, Gastroenterology.
[29] Ralf Bartenschlager,et al. Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.
[30] D. Burton,et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 , 2012, Proceedings of the National Academy of Sciences.
[31] J. Dubuisson,et al. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets , 2012, Gut.
[32] C. Scagnolari,et al. Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis , 2012, Virus Research.
[33] F. Cosset,et al. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation , 2011, Expert Reviews in Molecular Medicine.
[34] H. Drummer,et al. The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. , 2011, The Journal of general virology.
[35] F. Penin,et al. Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2 , 2010, Journal of Virology.
[36] Sven Bergmann,et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.
[37] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[38] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[39] Thomas Berg,et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.
[40] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[41] Jon Wakefield,et al. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.
[42] F. Penin,et al. An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies , 2005, Journal of Virology.
[43] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[44] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[45] J. Skehel,et al. Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.